Profiling Parkinson's disease
Primary objective: To evaluate the role of existing and novel quantitative biomarkers in understanding the heterogeneity in the Parkinson’s phenotype (i.e. rate of progression, cognitive and neuropsychiatric impairment and motor dysfunction) and predicting treatment response as well as the occurrence of ADRs over a three-year period.
Secondary Objective: To develop a biobank containing comprehensive and uniformly acquired longitudinal clinical data and biological samples for identification and validation of biomarker panels and data-driven approaches to unravel heterogeneity in the Parkinson’s phenotype (i.e. rate of progression, cognitive and neuropsychiatric impairment and motor dysfunction), treatment response and occurrence of ADRs.
Start year: 2021
End Year: 2026
Funding: ZonMW, AbbVie B.V., Pharmo Institute NV, Hoffmann-La Roche, H. Lundbeck A/S, Centre for Human Drug Research, Hersenstichting Nederland, Parkinson Vereniging, Stichting Alkemade-Keuls, Ventana Medical Systems, Inc
Design
- Study design
- Cohort
- Follow Up
- - Yearly followup, for Parkinson patients. - Twice yearly for a subgroup of Parkinson patients. - One follow-up, two years after baseline assessment, for healthy controls.
Number of participants
- Number of participants
- 1,250
- Number of participants with biosamples
- 1,250
- Supplementary Information
-
- Participants: 1250 participants with Parkinson's Disease; 265 healthy control participants
- Biosamples: 1250 participants with Parkinson's Disease; 265 healthy control participants
- Imaging data: 100 participants with Parkinson's Disease
Access
Available on request
| Data | |
| Biosamples | |
| Imaging |
Timeline
Populations
All participants: patients and healthy controls
Selection Criteria
- Minimum age
-
18
- Newborns
- Twins
- Countries
-
- Netherlands
- Health Status
-
- Parkinson's disease (patients)
- No history of neurological disorders that affect the brain or central nervous system (healthy controls)
Recruitment
Number of participants
- Number of participants
- 1,615
- Number of participants with biosamples
- 1,615
- Supplementary Information
- 1250 Participants with Parkinson's Disease, 265 healthy control participants
Data Collection Event
All participants
- Start Date
-
2021-07
- End Date
-
2026-12
- Data sources
-
- Others : Inertial Measurement Unit data / Medication
People diagnosed with PD 2 years or fewer at baseline.
Selection Criteria
- Minimum age
-
18
- Newborns
- Twins
- Countries
-
- Netherlands
- Health Status
-
- Parkinson's disease
Recruitment
Number of participants
- Number of participants
- 675
- Number of participants with biosamples
- 675
Data Collection Event
- Start Date
-
2021-07
- End Date
-
2026-12
- Data sources
-
- Others : Inertial Measurement Unit data / Medication
People diagnosed with PD between 2 and 10 years at baseline.
Selection Criteria
- Minimum age
-
18
- Newborns
- Twins
- Countries
-
- Netherlands
- Health Status
-
- Parkinson's disease
Recruitment
Number of participants
- Number of participants
- 675
- Number of participants with biosamples
- 675
Data Collection Event
- Start Date
-
2021-07
- End Date
-
2026-12
- Data sources
-
- Others : Inertial Measurement Unit data / Medication
gender and age matched healthy control participants
Selection Criteria
- Minimum age
-
18
- Newborns
- Twins
- Countries
-
- Netherlands
- Health Status
-
- No history of neurological disorders that affect the brain or central nervous system
Recruitment
Number of participants
- Number of participants
- 265
- Number of participants with biosamples
- 265
Data Collection Event
- Start Date
-
2021-07
- End Date
-
2026-12
- Data sources
-
- Others : Inertial Measurement Unit data / Medication